105 related articles for article (PubMed ID: 10988359)
1. Protective role of IL-2 during activation of T cells with bryostatin 1.
Kos FJ; Cornell DL; Lipke AB; Graham LJ; Bear HD
Int J Immunopharmacol; 2000 Aug; 22(8):645-52. PubMed ID: 10988359
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PMA-induced human T cell proliferation by bryostatin is associated with enhanced degradation of conventional protein kinase C (cPKC): Ca2+ signals restore mitogenic activity without abrogating enhanced cPKC degradation.
Galron D; Tamir A; Altman A; Isakov N
Cell Immunol; 1994 Oct; 158(1):195-207. PubMed ID: 8087865
[TBL] [Abstract][Full Text] [Related]
3. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.
Esa AH; Boto WO; Adler WH; May WS; Hess AD
Int J Immunopharmacol; 1990; 12(5):481-90. PubMed ID: 2210911
[TBL] [Abstract][Full Text] [Related]
4. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.
Lind DS; Tuttle TM; Bethke KP; Frank JL; McCrady CW; Bear HD
Surg Oncol; 1993 Oct; 2(5):273-82. PubMed ID: 8305969
[TBL] [Abstract][Full Text] [Related]
5. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
6. Activation of human T lymphocytes by bryostatin.
Hess AD; Silanskis MK; Esa AH; Pettit GR; May WS
J Immunol; 1988 Nov; 141(10):3263-9. PubMed ID: 3263418
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.
Scheid C; Prendiville J; Jayson G; Crowther D; Fox B; Pettit GR; Stern PL
Cancer Immunol Immunother; 1994 Oct; 39(4):223-30. PubMed ID: 7954524
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.
Trenn G; Pettit GR; Takayama H; Hu-Li J; Sitkovsky MV
J Immunol; 1988 Jan; 140(2):433-9. PubMed ID: 3257237
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells.
Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M
Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
Tuttle TM; Inge TH; Lind DS; Bear HD
Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
[TBL] [Abstract][Full Text] [Related]
12. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.
Hess AD; Bright EC
Transplantation; 1991 Jun; 51(6):1232-40. PubMed ID: 1646506
[TBL] [Abstract][Full Text] [Related]
13. Precursor frequency analysis of bryostatin activated lymphocytes.
Fleming MD; Barrett SK; Bear HD
J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153
[TBL] [Abstract][Full Text] [Related]
14. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang H; Mohammad RM; Werdell J; Shekhar PV
Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
[TBL] [Abstract][Full Text] [Related]
15. Bryostatin 1 activates T cells that have antitumor activity.
Tuttle TM; Inge TH; Wirt CP; Frank JL; McCrady CM; Bear HD
J Immunother (1991); 1992 Aug; 12(2):75-81. PubMed ID: 1504056
[TBL] [Abstract][Full Text] [Related]
16. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
17. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
18. Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity.
Levine BL; May WS; Tyler PG; Hess AD
J Immunol; 1991 Nov; 147(10):3474-81. PubMed ID: 1834742
[TBL] [Abstract][Full Text] [Related]
19. Nordihydroguaiaretic acid blocks IL-2-independent lymphocyte proliferation and enhances responses to PPD.
Esa AH; Converse PJ
Scand J Immunol; 1996 Feb; 43(2):127-33. PubMed ID: 8633191
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
